LIGAND PHARMACEUTICALS INC (LGND) Cash flow
Market cap
$4.7B
P/E ratio
38.2x
| 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Depreciation & amortization | 3 | 3 | 3 | 3 | 3 | 11 | 12 | 15 | 18 | 26 | 51 | 52 | 37 | 35 | 34 |
| Stock-based compensation | 3 | 4 | 6 | 11 | 12 | 19 | 25 | 21 | 25 | 31 | 39 | 60 | 26 | 41 | 47 |
| Cash from operations | -1 | 1 | 21 | 21 | 42 | 63 | 94 | 194 | -29 | 55 | 79 | 138 | 50 | 97 | 49 |
| Capital expenditures | -0 | -1 | -0 | -0 | -0 | -2 | -2 | -1 | -3 | -4 | -9 | -18 | -4 | -2 | -0 |
| Cash from investing | -25 | 1 | -5 | -2 | -113 | -143 | -84 | -423 | 467 | 232 | 31 | 164 | -12 | -144 | -377 |
| Repurchases of common stock | 0 | - | - | 68 | 0 | 4 | 2 | 123 | 453 | 78 | - | - | - | - | 15 |
| Repayments of term debt | - | 10 | 20 | 9 | - | - | - | 218 | 27 | 222 | 156 | 261 | 77 | - | - |
| Cash from financing | 30 | 4 | -16 | 130 | 8 | 2 | -8 | 329 | -485 | -311 | -138 | -276 | -60 | 97 | 428 |
| Free cash flow | |||||||||||||||
| FCF margin (%) |